Targeting primary cilia to treat glaucoma
View Patent ↗Methods for reducing intraocular pressure and treating glaucoma are disclosed. The methods include administering to an individual a composition comprising a TRPV4 agonist.
1. A method for reducing intraocular pressure in an individual in need thereof, the method comprising: administering a composition comprising a transient receptor potential cation channel subfamily V member 4 (TRPV4) agonist to the individual, wherein the TRPV4 agonist is (N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide).
2. The method of claim 1 , wherein the individual is administered from about 50 ng/g body weight to about 500 ng/g body weight of the TRPV4 agonist.
3. The method of claim 1 , wherein the individual is administered the TRPV4 agonist using a method selected from the group consisting of topically, periocularly, intraocularly, and combinations thereof.
4. The method of claim 3 , wherein the individual is administered the TRPV4 agonist using intraocular injection.
5. A method for treating glaucoma in an individual in need thereof, the method comprising: administering a composition comprising a transient receptor potential cation channel subfamily V member 4 (TRPV4) agonist to the individual, wherein the TRPV4 agonist is (N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide).
6. The method of claim 5 , wherein the individual is administered from about 50 ng/g body weight to about 500 ng/g body weight of the TRPV4 agonist.
7. The method of claim 5 , wherein the individual is administered the TRPV4 agonist using a method selected from the group consisting of topically, periocularly, intraocularly, and combinations thereof.
8. The method of claim 7 , wherein the individual is administered the TRPV4 agonist using intraocular injection.
9. A method for treating a ciliopathy in an individual in need thereof, the method comprising: administering a composition comprising a TRPV4 agonist to the Individual, wherein the TRPV4 agonist is (N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide).
10. The method of claim 9 , wherein the individual is administered from about 50 ng/g body weight to about 500 ng/g body weight of the TRPV4 agonist.
11. The method of claim 9 , wherein the individual is administered the TRPV4 agonist using a method selected from the group consisting of topically, periocularly, intraocularly, and combinations thereof.
12. The method of claim 11 , wherein the individual is administered the TRPV4 agonist using intraocular injection.
13. The method of claim 9 , wherein the ciliopathy is selected from the group consisting of retinitis pigmentosa, renal cysts, polydactyly, and developmental delays.